ARTBIO

ActiveBorn in Norway, based elsewhere

Radiopharmaceuticals · Norway

HQBuilt on science from the University of Oslo; run from Cambridge, Massachusetts and Oslo

Last roundSeries B · Jul 2025

Country of originNorwayBorn here, based elsewhere

BasedBuilt on science from the University of Oslo; run from Cambridge, Massachusetts and Oslo

Born in Norway, based elsewhere

ARTBIO is listed by the Norway ranking as a company founded by Norway-linked founders but headquartered abroad: it is not ranked in Norway. Built on science from the University of Oslo; run from Cambridge, Massachusetts and Oslo.

Funding history

Date	Round	Amount	Type	Investors
Jul 2025	Series B	USD 132M	—	Sofinnova Investments, B Capital, F-Prime, Omega

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Norway · all sectors	Born here, based elsewhere	—	Edition 0 · October 2026	25 Nov 2026

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of ARTBIO as a PDF. It must answer at least one of these four questions, and stick to them:

ValuationWhat is ARTBIO worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back ARTBIO whether or not it has agreed: your intention joins the pool on ARTBIO, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back ARTBIO Or back biotech in Norway

Pool on ARTBIOBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run ARTBIO?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Norway

Full Norway ranking →

Calluna Pharma#3Biotech › immunology antibodiesHundreds of M$Gelato#1E-commerce › print on demandUnicorn Ardoq#2B2B software › enterprise architectureHundreds of M$Xeneta#4B2B software › freight rate intelligenceHundreds of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.